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Objective. We aimed to demonstrate safety and efficacy of intravenous (IV) low molecular weight iron dextran (LMWID) during
treatment of anemic stage 3 and 4 chronic kidney disease (CKD) patients. Methods. Efficacy data was obtained by retrospective chart
review of 150 consecutively enrolled patients. Patients were assigned per protocol to oral or IV iron, with IV iron given to those with
lower iron stores and/or hemoglobin. Iron and darbepoetin were administered to achieve and maintain hemoglobin at 10–12 g/dL.
Efficacy endpoints were mean hemoglobin and change in iron indices approximately 30 and 60 days after enrollment. Safety data was
obtained by retrospective review of reported adverse drug events (ADEs) following 1699 infusions of LMWID (0.5–1.0 g). Results.
Mean hemoglobin, iron saturation, and ferritin increased significantly from baseline to 60 days in patients assigned to LMWID
(hemoglobin: 11.3 versus 9.4 g/dL; iron saturation: 24% versus 12.9%; ferritin: 294.7 versus 134.7 ng/mL; all 𝑃 values < 0.0001). Iron
stores and hemoglobin were maintained in the group assigned to oral iron. Of 1699 iron dextran infusions, three ADEs occurred.
Conclusions. Treatment of anemia in CKD stages 3 and 4 with LMWID and darbepoetin is efficacious. The serious ADE rate was
0.06% per infusion.

1. Introduction
Erythropoiesis is optimized in chronic kidney disease by
treatment with iron and erythropoiesis-stimulating agents
(ESAs). For end-stage renal disease patients on hemodialysis,
intravenous (IV) iron is more efficacious than oral iron [1–3].
Potential advantages of IV iron include direct iron delivery to
bone marrow and tissue stores, large-dose delivery, and elimination of frequent gastrointestinal side effects associated with
oral iron treatment [4–8]. Among IV iron formulations, iron
isomaltoside, ferric carboxymaltose, and the iron dextrans
(IDs) can be administered in total dose infusion (TDI). Both
ferric gluconate and iron sucrose can be safely administered
as a bolus or short infusion at doses up to 250 mg and 300 mg,
respectively. Higher doses of either drug as a bolus or short

infusion have been associated with unpleasant vasoactive
and gastrointestinal symptoms [9, 10]. However, accelerated
regimens of high-dose IV iron sucrose (500 mg over 3 hours)
have been demonstrated to be safe in several studies [11–
13]. The safety and efficacy of ID in nondialysis chronic
kidney disease (ND-CKD) is less well reported, especially
for the low molecular weight iron dextran (LMWID) INFeD
[14]. Imferon, Dexferrum, and INFeD are the IDs that have
been used in the USA. The first two are high molecular
weight iron dextrans (HMWIDs); the last is an LMWIDs.
Imferon is no longer available; it was withdrawn by the
original manufacturer, Fisons, based on economic decisions
[15, 16]. These preparations are erroneously classified by some
as a single class of product with similar side-effect profile.
However, recently published literature revealed that LMWID
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has a different safety profile than HMWID. Several studies
have shown that HMWID is associated with more adverse
drug events (ADEs) than other iron preparations in the
market [17–20]. The level and methods of ADE reporting
vary between different studies. Some report the ADE rate per
episode of ID administered, others per unit ID infusion or per
patients treated. Moreover, there is no uniform definition of
what constitutes a “serious” adverse event [21].
After recent concerns about the safety of ESAs and
the current economic realities, the need for more effective
anemia management strategies is of paramount importance.
Incorporation of IV iron into the anemia treatment paradigm
is needed to achieve the lowest effective ESA dose. At
the Henry Ford Hospital Chronic Kidney Disease Clinic,
LMWID in conjunction with ESA is used for ND-CKD
anemia management using a computerized algorithm for
dosing (see Section 2). ID is infused in accelerated fashion
(1.5–2 hours) and in amounts considered to be TDI. This
study reports the 2-month outcomes of hemoglobin (Hb),
ferritin, and transferrin saturation (TSAT) in both IV and oral
treatment groups from baseline. The cumulative incidence of
ADEs related to ID in a cohort of 935 patients followed in
ND-CKD is also reported.

2. Methods
2.1. Safety. This study was conducted in two parts. For the
safety outcome, a retrospective chart review was done of
all ND-CKD patients who received iron dextran (INFeD)
between January 2001 and November 2005 in the outpatient
CKD clinic at Henry Ford Hospital, Detroit, Michigan.
The 936 ND-CKD subjects identified in the database each
received either 0.5 or 1.0 g infusion by peripheral vein over
1.5–2.0 hours. The dosing of INFeD during this study period
was at the discretion of the treating physician. None of our
patients were premedicated with diphenhydramine. Safety
endpoints were ADEs documented in the patients’ electronic
records. ADE rate were reported per episode of ID administered. All ADE presumed to be related to LMWID were
also reported to the Food and Drug Administration (FDA)
MedWatch. Serious ADEs were classified as cardiovascular
collapse and anaphylactoid shock. Moderate ADEs were
categorized as dyspnea, severe urticaria, chest discomfort, or
neck/back spasms. Mild ADEs were classified as headache,
dizziness, tachycardia, and hypertension in which the infusion was stopped but the patient subsequently completed the
infusion [22].
2.2. Efficacy. The efficacy outcomes were obtained from
analysis of the data of patients enrolled in the clinic’s computerized anemia management program (CAMP) between
December 2005 and January 2007. CAMP is designed to
treat anemia of CKD using darbepoetin alpha (DA) and
iron treatment algorithms. After manual data input, the iron
dosing algorithm prescribes no iron, oral iron, or 1 g of INFeD
over 1.5–2 hours based on Hb, TSAT, and ferritin levels. At
all times, iron “sufficiency” is to be achieved/maintained with
oral or parenteral ID per the algorithm (Figure 1). ESA dosing
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is based on three separate protocols for first, second, and
maintenance DA doses with a target to achieve and maintain
Hb in the range of 10.0–12.0 g/dL. The first DA dose is based
on the entry Hb. The second dose is based on the initial DA
dose, initial Hb and current Hb. Maintenance DA doses are
based on trend analysis of the most recent Hb, the last two
DA doses and any increase or decrease in the last two doses.
All subjects were ≥18 years old, ND-CKD with an estimated glomerular filtration rate (GFR) of ≤60 mL/min, and
fulfilled criteria for iron deficiency anemia per the CAMP
protocol. For the 26-month period, 166 subjects were found
in the database of CAMP who received and completed IV or
oral iron treatment as prescribed by CAMP.
Sixteen patients were excluded because either their second evaluation day period exceeded 37 days from baseline or
the third evaluation day exceeded 37 days from second evaluation day. Among the remaining 150 patients, 50 received
LMWID and 100 received oral iron because their parameters
never fulfilled the criteria to receive IV iron per CAMP. Oral
iron was administered as Nephron FA. Each tablet contained
200 mg of ferrous fumarate (33% elemental iron), 40 mg of
ascorbic acid, 1 mg folate, 75 mg of sodium docusate, and all
B vitamins. Prior to being enrolled in CAMP, 32 of 50 patients
assigned to IV iron had received DA in the past three months.
In the oral iron group, 75 of 100 patients had received DA.
No patient in either group had received IV iron in the past
three months. Only 2 of 50 patients assigned to IV iron group
needed a second dose of LMWID on second evaluation.
The primary efficacy endpoint was the mean Hb in
each group. Secondary endpoints were iron indices (TSAT,
ferritin) at ≈30 and 60 days in each group as well as ESA dose
requirements. Since the two groups by protocol design were
assigned to different iron and ESA dosing, and dosing was
adjusted to reach or maintain a target goal; we only compared
mean differences between the two groups at the third clinic
visit (≈60 days).
2.3. Statistical Analysis. Categorical variables are presented
as frequencies and percentages. Continuous variables are
presented using mean ± standard deviation. Comparisons of
baseline characteristics between oral and IV iron groups were
tested using two-sample 𝑡-tests for continuous variables, and
chi-square and Fisher’s exact tests for categorical variables.
Intra-individual changes between time points for Hb, ferritin,
TSAT, and DA were tested using Student’s paired 𝑡-test. For
all analyses, a 𝑃 value < 0.05 was considered significant.
Statistical analysis was performed using SAS software version
9.2 (SAS Institute, Inc., Cary, NC) and graphs were produced
using STATA software version 10 (StataCorp LP, College
Station, TX).

3. Results
3.1. Demographics. For the 150 patients represented in the
efficacy analysis, baseline characteristics of both oral and
IV iron groups are listed in Table 1. There was no statistical
difference in age, race, or gender between frequencies of coronary artery disease, diabetes, and hypertension. However, the
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Ferritin
>500

Yes

TSAT
≥20%

No

TSAT
>30%

No

No

Hgb
≥10.5 g/dL

TSAT
≥20%
Yes

Yes
Yes

Yes

No

Yes

Hgb
≥10.5 g/dL

Oral iron

Low mol. wt.
iron dextran
1000 mg

No

No
No iron

Oral iron

Low mol. wt.
iron dextran
1000 mg

No iron

Figure 1: Computerized iron dosing protocol for CKD stages 3 and 4.

3.2. Safety. Over the 6-year study period, 935 ND-CKD
patients (488 stage 3 CKD and 447 stage 4 CKD) were treated
with ID. A total of 1699 infusions (14 × 1 gram and 1685 ×
0.5 gram doses) were administered over the study period
(1713 0.5 g equivalents). Three ADEs were reported. Only one
ADE was classified as serious. The overall ADE event rate
was 0.175% per 0.5 gram dose equivalents and 0.177% per
episode of IV iron infusion. The rate for serious ADE was
less than 0.06%. All three ADEs occurred in women (mean
age 70.3 years [range, 50–85 years]). All ADEs occurred with
the first dose and within 30 minutes of ID administration.
In these patients, a test dose did not predict the occurrence
of a subsequent ADE. Of the three patients with ADEs, one
experienced a severe reaction requiring 1 mg of epinephrine
to reverse hypotension and bradycardia; one experienced a
moderate reaction with dyspnea and responded to diphenhydramine; the third experienced a moderate reaction with a
rash that responded to diphenhydramine and dexamethasone
treatment. None of the three patients required hospitalization
or Emergency Department evaluation. There were no fatalities noted from ID administration during the 6-year study
period.
3.3. Efficacy. Figures 2, 3, 4, and 5 show the mean Hb, TSAT,
ferritin, and DA levels, respectively, over time by treatment
group. Tables 2 and 3 display pairwise comparison of these
parameters at three evaluation days in the iron dextran
group (IDG) and oral group (OG), respectively. The IDG
showed significant improvement in the mean Hb compared
to baseline at days 30 (10.7 versus 9.4 g/dL; 𝑃 < 0.0001) and

11.5

Hb (g/dL)

patients who received IV iron had a higher frequency of
congestive heart failure. Baseline Hb, TSAT, and ferritin were
lower in the IV group, as expected based on CAMP. For the
935 patients represented in the safety analysis, the mean age
was 63.9 ± 15.0 years; 60% were women; 64% were African
American, 32% white, and 4% either Asian or Hispanic.

⧫
𝑃 < 0.0001
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𝑃 < 0.0001 ⧫

10.5
10
9.5
9
Baseline

30 days

60 days

Evaluation day
Versus baseline
⧫ Not significant versus baseline

IV
Oral

Figure 2: Mean hemoglobin levels ± SD by treatment group over
duration of study. 𝑃 values compare 30 and 60 days to baseline values
for the IV group.

60 (11.3 versus 9.4 g/dL; 𝑃 < 0.0001). In the OG, mean Hb
also increased at 30 days (11.1 versus 10.9 g/dL; 𝑃 = 0.0258)
and 60 days (11.3 versus 10.9 g/dL; 𝑃 = 0.0003).
TSAT in IDG improved significantly by day 30 (23.4
versus 12.9; 𝑃 < 0.0001). The effect of 1 gram ID on TSAT was
maintained through day 60 (24.0 versus 12.9; 𝑃 < 0.0001).
The mean TSAT was maintained by oral iron and increased
slightly from baseline (25.0 versus 23.2; 𝑃 = 0.0401). A robust
increase in ferritin from baseline was observed in the IDG
at day 30 (359.0 versus 134.7; 𝑃 < 0.001). The iron stores as
reflected by ferritin remained higher than baseline at day 60
(294.0 versus 134.7; 𝑃 < 0.001). No statistically significant
change in ferritin was seen in the OG by 60 days (220.2 versus
216.7; 𝑃 = 0.8339). DA use, as prescribed by the algorithm,
was greater in IDG than OG at all evaluation days (𝑃 <
0.001) as shown in Figure 5. By day 60, Hb, TSAT, and ferritin
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Table 1: Patient demographics and baseline characteristics.

Baseline results
Demographics
Age, years
Race, 𝑛 (White/Black/Asian/Hispanic)
Gender, 𝑛 (male/female)
Former medical history, 𝑛
Congestive heart failure
Coronary artery disease
Hypertension
Diabetes
Laboratory
Hb (g/dL)
TSAT%
Ferritin (ng/mL)

IV iron
(𝑛 = 50)

Oral iron
(𝑛 = 100)

𝑃 value

69.1 ± 12.9
10/40/0/0
23/27

65 ± 13.5
14/83/1/2
45/55

0.061†
0.654#
1.000𝜒

18 (36%)
12 (24%)
49 (98%)
25 (50%)

13 (13%)
16 (16%)
97 (97%)
54 (54%)

0.001𝜒
0.236𝜒
1.000#
0.643𝜒

9.4 ± 0.8
12.9 ± 4.0
134.7 ± 151.5

10.9 ± 1.2
23.2 ± 5.8
216.7 ± 146.0

<0.001†
<0.001†
<0.005†

†

2-sample 𝑡-test, 𝜒 Chi-square, # Fisher exact.
Demographics are reported as frequencies except for age which is reported as a mean. Variables under past medical history are reported as frequencies with
percentages in parenthesis. Laboratory parameters are reported as means + SD. 𝑃 value > 0.05 was considered nonsignificant (n.s.).

Table 2: Parameter comparison at three evaluation points in iron dextran group.
Parameter
Hb (g/dL)

TSAT%

Ferritin (ng/mL)

Evaluation days
Baseline versus day 30
Baseline versus day 60
Day 30 versus day 60
Baseline versus day 30
Baseline versus day 60
Day 30 versus day 60
Baseline versus day 30
Baseline versus day 60
Day 30 versus day 60

were not statistically different between the IDG and OG (Hb:
11.3 ± 1.1 versus 11.3 ± 1.2; TSAT: 24.0 ± 9.9 versus 25.0 ± 8.4;
ferritin: 294.0±254.6 versus 220.2±213.5; all 𝑃 values > 0.20).

4. Discussion
4.1. Safety. Four main iron preparations are used in the USA:
two iron dextrans (LMWID, INFeD; HMWID, Dexferrum),
sodium ferric gluconate (Ferrlecit), iron sucrose (Venofer),
and ferumoxytol (Feraheme) [23–27]. Both INFeD and Dexferrum are FDA approved for patients with documented iron
deficiency in whom oral administration was unsatisfactory
or not possible. In addition to hemodialysis patients [1, 28,
29], the efficacy of iron dextran has been demonstrated in
different patient populations with documented iron deficiency, such as patients with pregnancy-related anemia [30],
cancer patients [31], surgical patients who refuse transfusions
[32], and patients on ambulatory peritoneal dialysis [33,
34]. Among the iron preparations used in the USA, the
iron dextrans can be administered as TDI [14, 34–36]. The
accelerated TDI of iron dextran was also recently reported
safe by Auerbach et al. [37]. Slow infusion of high-dose

Group means ± SD
9.4 ± 0.8
10.7 ± 1.0
9.4 ± 0.8
11.3 ± 1.1
10.7 ± 1.0
11.3 ± 1.1
12.9 ± 4.0
23.4 ± 8.7
12.9 ± 4.0
24.0 ± 9.9
23.4 ± 8.7
24.0 ± 9.9
134.7 ± 151.5
359.0 ± 295.6
134.7 ± 151.5
294.0 ± 254.6
359.0 ± 295.6
294.0 ± 254.6

𝑃 value
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0058

ID (0.5–1.0 g) is frequently termed TDI because it provides
enough iron to produce the desired Hb increase as well
as to replete tissue and reticuloendothelial stores. TDI is
deemed appropriate by the National Kidney Foundation’s
Kidney Disease Outcomes Quality Initiative guidelines in
CKD patients who despite oral iron supplementation have
persistent evidence of iron deficiency [38]. However, TDI
is not FDA approved because of high incidence of delayed
arthralgias and myalgias [39]. These symptoms usually occur
about 24 hours later, abate without therapy, and should not
be considered ADEs. Both the HMWID and LMWID carry a
black box warning regarding the risk of anaphylactoid reactions. Although anaphylaxis has been reported with LMWID,
its incidence is rare (<1 : 200 000). Acute chest and back pain
at times are mistakenly described as anaphylaxis attributable
to LMWID. These symptoms when not accompanied by
hypotension, tachypnea, tachycardia, wheezing, stridor, or
orbital edema are harmless, abate in few minutes, and do not
automatically qualify for treatment by diphenhydramine or
epinephrine. Further premedication with diphenhydramine
can cause tachycardia, sweating, somnolence, supraventricular tachycardia, and hypotension, all of which are attributed
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Table 3: Parameter comparison at three evaluation points in oral iron group.
Parameter
Hb (g/dL)

TSAT%

Ferritin (ng/mL)

Group means ± SD

Evaluation days
Baseline versus day 30
Baseline versus day 60
Day 30 versus day 60
Baseline versus day 30
Baseline versus day 60
Day 30 versus day 60
Baseline versus day 30
Baseline versus day 60
Day 30 versus day 60

10.9 ± 1.2
10.9 ± 1.2
11.1 ± 1.3
23.2 ± 5.8
23.2 ± 5.8
24.0 ± 7.3
216.7 ± 146.0
216.7 ± 146.0
221.9 ± 167.0

30
𝑃 < 0.0001 ⧫

Darbepoetin (mcg)

TSAT (%)

20

10
Baseline

30 days
Evaluation day

Versus baseline
⧫ Not significant versus baseline

60 days

𝑃 < 0.0001

400

𝑃 < 0.0001

300

⧫

⧫

200
100

Baseline

30 days
Evaluation day

Versus baseline
⧫ Not significant versus baseline

⧫

200
150
⧫

60 days

IV
Oral

Figure 4: Mean ferritin ± SD by treatment group over duration of
study. 𝑃 values compare 30 and 60 days to baseline values for the IV
group.

⧫

100
50
Baseline
⧫

IV
Oral

Figure 3: Mean transferrin saturation (TSAT) ± SD levels by
treatment group over duration of study. 𝑃 values compare 30 and
60 days to baseline values for the IV group.

500

⧫

𝑃 < 0.0001⧫

15

Ferritin (ng/mL)

11.1 ± 1.3
11.3 ± 1.2
11.3 ± 1.2
24.0 ± 7.3
25.0 ± 8.4
25.0 ± 8.4
221.9 ± 167.0
220.2 ± 213.5
220.2 ± 213.5

250

25

𝑃 value
0.0258
0.0003
0.0458
0.3318
0.0401
0.2889
0.4722
0.8339
0.9215

30 days
Evaluation day

60 days

Not significant versus baseline
IV
Oral

Figure 5: Darbepoetin alfa (mcg) ± SD utilization by treatment
group over duration of study.

to the IV iron [40]. Prior to initiating IV iron dextran therapy,
the package insert states “administer a test INFeD dose prior
to the first therapeutic dose. If no signs or symptoms of
anaphylactic-type reactions follow the test dose, administer
the full therapeutic INFeD dose” [23].
Criticism and controversy surrounding iron dextran’s side
effect profile surfaced in its postmarketing phase. Although
US sales for iron preparations have soared since the late
1990s, there has been a noticeable decline in ID use. This
decline was likely secondary to the market’s introduction
of newer IV formulations and at least partially due to
the adverse events reported in several studies [15, 41–43].
However, none of these observational studies could establish whether other iron formulations possess a superior
adverse effect profile than LMWID. Moreover, in 2010, the
FDA issued a warning letter to Luitpold Pharmaceuticals
to stop claiming a safety advantage over iron dextrans in
the absence of comparative clinical trials (pers comm, M
Safarik, Department of Health and Human Services, FDA).
Hamstra et al. administered 2099 IV injections of iron
dextran (Imferon) to 481 patients. Three life-threatening,
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immediate anaphylactoid and eight severe, delayed reactions
were observed [15]. Bailie et al. compared ADEs among three
iron preparations (iron dextran, Ferrlecit, and Venofer) using
data from the Freedom of Information surveillance database
from January 1997 to September 2002. The iron formulations
were administered and reported per 100 mg dose equivalents.
The all-event reporting rates for iron dextran, sodium ferric
gluconate, and iron sucrose were 29.2, 10.5, and 4.2 reports
per million 100 mg dose equivalents, while the all-fatal-event
reporting rates were 1.4, 0.6, and 0.0 reports per million
100 mg dose equivalents [41]. This paper did not distinguish
between HMWID and LMWID formulations, nor did it
characterize the population being studied. It estimated ADEs
per dose of iron administered. Faich and Strobos reviewed
the spontaneous adverse reaction reporting of iron dextran
in the USA and sodium ferric gluconate in Germany and
Italy from 1976 to 1996. Data was gathered from the World
Health Organization, pharmaceutical manufacturers, and the
German Health Bureau. The 21-year period had 74 reports
of suspected allergic or anaphylactoid reactions for sodium
ferric gluconate complex and 196 comparable reports for
iron dextran in the US. No fatalities were reported for
iron gluconate. However, 31 fatalities were reported for
iron dextran [42]. The comparison was made based on the
assumption that the extent of drug exposure to both IV
preparations was similar during that time period. Data for
iron dextrans was combined because reporting databases
did not distinguish between the different iron dextran formulations. Fishbane conducted a retrospective chart review
of 573 hemodialysis patients treated with IV iron dextran
(INFeD) over a 2-year period. Twenty-seven patients (4.7%)
had adverse reactions. Four patients (0.7%) had reactions
classified as serious [43]. Although the ADE rate appears high
in this study, the unit of evaluation was neither the dose
nor the episode of IV iron dextran administration but the
patient.
Clinicians should be aware that LMWID and HMWID
are not clinically interchangeable. Several publications have
demonstrated higher rates of adverse events with HMWID
[17–20]. Chertow and colleagues examined ADEs among
three iron formulations (HMWID, LMWID, and sodium
ferric gluconate) using data from the FDA during 1998–2000.
The total number of reported parenteral iron-related ADEs
was 1981 among approximately 21 060 000 doses. The total
major ADE rates were significantly higher among recipients
of HMWID and sodium ferric gluconate complex than
among recipients of LMWID [17].
In 2006, Chertow et al. examined ADEs among four iron
formulations (HMWID, LMWID, sodium ferric gluconate
complex, and iron sucrose) using FDA MedWatch data from
2001 to 2003. The rates of both total and life-threatening
ADEs were significantly higher among recipientsof HMWID
than LMWID or other iron formulations. The total ADE
reporting rates for Dexferrum, INFeD, sodium ferric gluconate, and iron sucrose were 129, 40.2, 19.4, and 19.8
reports per million/100 mg equivalents, respectively, whereas
the absolute rates of life-threatening events were 11.3, 3.3,
0.6, and 0.9 per million. The investigators point out that
several life-threatening ADEs did not specify the iron dextran
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formulation but were attributed to LMWID, without definitive data. However, when HMWID was avoided, the other
formulations were safe with an estimated serious adverse
event rate of <1 : 200,000 [18]. In 2001, Fletes et al. reported
on iron dextran-related ADEs using data from Fresenius
Medical Care North America (FMCNA) clinical variance
reports. Among 841 252 IV iron dextran administrations
from October 1998 through March 1999 in patients with endstage renal disease, there were 165 reported suspected ADEs,
corresponding to an overall rate of 0.000196%, or approximately 20 per 100 000 doses. Eighteen patients required
hospitalization and one patient died. Dyspnea, hypotension,
and neurological symptoms were the most common major
ADEs. ADEs were 8.1-fold more common among patients
administered Dexferrum. The paper did not compare the
severity of ADEs between the two iron formulations. Patients
with ADEs had a mean age of 61.7 years; almost 50% of ADEs
occurred in women; 66% occurred on initial dosing and with
a median time of 5 minutes into dosing [19].
In our study, all ADEs occurred in older women (mean
age 70.3 years), on initial dosing, and within 30 minutes
of dosing. None of our patients required emergency evaluation, was hospitalized, or had fatal outcomes. While the
retrospective nature of this study would likely underestimate
minor reactions, it likely offers a reasonable estimation of
major adverse events. Our major ADE rate was 1 per 1699
total iron dextran infusions. Our major ADE rate per 100 mg
dose would translate to 12 per 100,000. However, we strongly
feel that ADEs reported per episode of IV iron administered
better reflect the true event rate. The study also shows that
slow infusion of high-dose INFeD is well tolerated in NDCKD patients. Unlike the nondextran IV formulations where
repeated IV infusions are required to achieve iron repletion,
it can be conveniently administered in a single clinic visit.
4.2. Efficacy. Efficacy studies of IV iron undertaken in
predialysis chronic renal failure have yielded contradictory
results. Some randomized controlled trials have shown that
IV iron is superior to oral iron in raising Hb in ND-CKD
patients [44–46] whereas other trials failed to demonstrate
the same [47–49]. Only one trial [47] was conducted exclusively in non-ESA-treated patients. Aggarwal et al. [44]
randomized 40 patients to either oral ferrous sulfate, 200 mg
three times a day (TID), or iron dextran, 100 mg IV (Imferon)
twice a month, and followed for up to 3 months. All patients
were given ESA therapy. IV iron dextran was more effective
than oral iron sulfate in increasing Hb and in improving iron
parameters. Van Wyck et al. [45] randomized 188 ESA-treated
and non-ESA-treated patients to either oral ferrous sulfate,
325 mg for 56 days, or iron sucrose, 1 g IV in divided doses
over a 2-week period. IV iron sucrose was more effective
than oral ferrous sulfate in improving iron indices and in
increasing Hb levels by at least 1 g/dL at any time point
during the study. Spinowitz et al. [46] randomized 304 ESAtreated and non-ESA-treated patients to either two 510 mg
of ferumoxytol or 200 mg of elemental iron for 21 days. At
day 35, ferumoxytol significantly increased iron indices and
hemoglobin compared to oral iron.
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Charytan et al. [48] randomized 96 patients to either
oral iron for 29 days or iron sucrose 200 mg IV once a week
for 5 doses and followed patients for 43 days. No significant
difference was found between the two groups in Hb levels, but
serum ferritin levels improved more in the IV iron sucrose
group. Stoves et al. [49] randomized 45 patients to either oral
ferrous sulfate, 200 mg TID, or iron sucrose, 300 mg IV once
a month, and followed them for an average of 5.2 months.
All patients were simultaneously started on ESA, and the
dose was adjusted according to a preestablished protocol.
Although serum ferritin improved more in the IV group, iron
sucrose was not superior to ferrous sulfate in improving Hb
or decreasing the ESA doses. Agarwal et al. [47] showed
that ferrous sulfate, 325 mg three times a day × 42 days, and
sodium ferric gluconate, 250 mg IV weekly × 4, similarly
increase Hb in anemic iron-depleted ND-CKD patients not
receiving ESAs.
The aim of our study was to demonstrate the efficacy
of the computerized anemia management protocol. We
used IV iron in the form of LMWID. ID allows for highdose infusions, giving it a practical advantage over other
IV formulations. The marketed “safer preparations” require
smaller, more frequent infusions over a longer period of
time. These tend to be more costly in terms of IV tubing,
monitoring, IV access, nursing, and allotted time. In theory,
at least, repeated injury to the venous system poses potential
problems with future venous access. In our protocol, in the
group assigned to LMWID + ESA, Hb increased by 1.3 ±
1 g/dL and 1.9±1 g/dL at days 30 and 60, respectively. Despite
the robust rise in Hb in the IDG and the incorporation
of transferrin bound iron to erythroid precursors, TSAT
increased considerably at days 30 (23.4 versus 12.9; 𝑃 <
0.0001) and 60 (24.0 versus 12.9; 𝑃 < 0.0001). Iron stores
as reflected by ferritin increased significantly from baseline
at day 30 and remained higher than baseline at day 60. By
≈60 days, mean Hb, TSAT, and ferritin in IDG all increased
to levels dictating transition to oral iron replacement per
protocol (Figure 1). Our results support that LMWID when
combined with ESA is efficacious in raising Hb and replenishing iron stores in as early as ≈30 days in ND-CKD
patients. It also supports that high-dose LMWID should be
considered in ND-CKD patients who fail or cannot tolerate
oral iron.
The limitation of this study is its retrospective design
which is subject to reporting bias. Adherence to oral iron was
not guaranteed. Patients were not segregated into ESA naive
and nonnaive. A predominant fraction of the patients in both
groups had already been managed in the CKD clinic and had
received DA in the three months prior to being enrolled in
CAMP.
4.3. Costs. Table 4 represents the Average Selling Price (ASP)
for different iron formulations based on Centers for Medicare
and Medicaid Services for the fourth quarter of 2012. In the
USA, the ASP of ferumoxytol is more than all the other
formulations. The ASPs of iron sucrose and ferric gluconate
are comparable. Both of these drugs have higher ASPs than
the iron dextrans.
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Table 4: Average selling price (ASP) based on Centers for Medicaid
and Medicare Services.
Product name
Iron dextran (Infed)
Iron dextran (Dexferrum)
Iron sucrose (Venofer)
Sodium ferric gluconate (Ferrlecit)
Ferumoxytol (Feraheme)

ASP per gram
$240.0
$240.0
$285.0
$265.2
$638.0

4.4. Prospects for Future. Each of the currently available
parenteral iron preparations has safety or convenience limitations in patients not on dialysis. The nondextran formulations
available in the USA are not recommended for TDI, and
multiple administrations must be scheduled. In Europe, two
other formulations are approved for TDI in 15 minutes: ferric
carboxymaltose (1000 mg) and iron isomaltoside (20 mg/kg).
Ferumoxytol is approved in the USA [37], and there might
be emerging data that it could be given in TDI (abstract,
Am Soc Hematol 54th Annual Meeting, 2012). However,
the characteristics of the ADE make it difficult to conduct
comparative safety studies between the different formulations
with sufficient methodological consistency and statistical
power. Moreover, adequately powered prospective comparative trials between two iron formulations will likely never be
done due to the large sample sizes needed. For example, at
90% power, to detect a difference between iron dextran with
our reported serious ADE rate (1/1699) and an IV formulation
with half as common serious ADEs, about 114,000 patients are
required in each group.

5. Conclusion
Our study supports the use of LMWID (INFeD) in TDI.
It is safe and effective in the treatment of iron deficiency
in ND-CKD. Because fatal anaphylactic reactions have been
reported after administration of iron dextran injection, the
drug should be given only when resuscitation techniques
and treatment of anaphylactic and anaphylactoid shock are
readily available. Our study did not show that higher doses of
ID were associated with worse ADE rates. If other potential
formulations are used, ADE profile, potential benefits, and
relative costs should be established.
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